Teclistamab (Tec)

DRUG4 trials

Sponsors

University of Heidelberg Medical Center, Peking University People's Hospital, Peking Union Medical College Hospital

Conditions

AL AmyloidosisMultiple Myeloma

Phase 2

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

RecruitingNCT05695508

University of Heidelberg Medical CenterMultiple Myeloma

Start: 2022-12-01End: 2029-09-15Target: 160Updated: 2025-12-24

Teclistamab in Previously Treated AL Amyloidosis

RecruitingNCT06935162

Peking Union Medical College HospitalAL Amyloidosis

Start: 2025-05-21End: 2028-12-31Target: 30Updated: 2025-05-25

Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis

RecruitingNCT07079423

Peking Union Medical College HospitalAL Amyloidosis

Start: 2025-06-28End: 2027-12-31Target: 35Updated: 2025-07-23

Unknown Phase

Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis

RecruitingNCT06699394

Peking University People's HospitalAL Amyloidosis

Start: 2025-03-29End: 2026-12-31Target: 20Updated: 2025-04-24

Related Papers

Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy

Blood2025-11-03